Chemistry:Delocamten

From HandWiki

Delocamten (development code MYK-224) is a small-molecule cardiac myosin inhibitor developed by Bristol Myers Squibb for hypertrophic cardiomyopathy.[1][2][3]

References

  1. ↑ Lehman, Sarah J.; Crocini, Claudia; Leinwand, Leslie A. (June 2022). "Targeting the sarcomere in inherited cardiomyopathies" (in en). Nature Reviews Cardiology 19 (6): 353–363. doi:10.1038/s41569-022-00682-0. ISSN 1759-5010. PMID 35304599. 
  2. ↑ Sebastian, Sneha Annie; Padda, Inderbir; Lehr, Eric J.; Johal, Gurpreet (September 2023). "Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy". American Journal of Cardiovascular Drugs 23 (5): 519–532. doi:10.1007/s40256-023-00599-0. PMID 37526885. 
  3. ↑ Packard, Elizabeth; de Feria, Alejandro; Peshin, Supriya; Reza, Nosheen; Owens, Anjali Tiku (December 2022). "Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy". Cardiology and Therapy 11 (4): 491–507. doi:10.1007/s40119-022-00283-5. PMID 36243823. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Delocamten&oldid=4029285"